Demonstrating Profitability for the Seventh Consecutive Year, mProve Health Moves Growing Team into New Headquarter Offices
WASHINGTON, DC – May 22, 2017, mProve Health, a leading provider of mobile technologies used by life science organizations to connect and engage patients with global clinical research studies, announces unprecedented 12-month growth and the addition of 25% more new pharmaceutical companies and CROs to its client base. With contracts for research studies at 18 of the top 20 pharmaceutical companies and more than 15,000 clinical research sites in over 60 countries engaged to enroll patients on mProve’s applications, the company is expanding. mProve Health recently made a strategic move into new, industrial- and tech-inspired, open-concept offices in the Washington, DC metro area. This comes following 16 new hires in the past 12 months and the establishment of a UK-based team in London.
“mProve Health has experienced record growth in the past 12 months,” says Jeff Lee, Founder and CEO. “Our traction among top 20 pharmaceutical companies is a direct result of our team and their ability to consistently deliver high-quality software and services. Opening our new Washington, DC headquarters, outfitted to attract and retain the best and brightest, was a strategic move to best position us for the future.” Leaving behind a startup-style office space, and moving the company into new, custom-designed headquarters will allow the company to plant firm roots.
mProve Health, founded in 2010, launched with a mobile technology product for patient recruitment that provides a call-to-action (i.e. “text KEYWORD to NUMBER”) to existing clinical research study advertisements. It has since expanded its offerings to include mobile technology for patient engagement and electronic patient reported outcomes (ePRO). Its ePRO product, mPulse, has contributed the most to revenue growth in the past 12 months, due to a 200 percent increase in new study contracts. mPulse is uniquely positioned in the marketplace because it delivers validated trial instruments, or market research surveys, along with patient engagement features, such as reminders, visit schedule details, and reference information, all in a single mobile app. This creates “one stop shop” access to study services that improve the patient’s experience, and boost utilization of diaries, patient compliance and study completion rates.
Commenting on the rapid development of the market, Jim Kremidas, Executive Director of the Association of Clinical Research Professionals (ACRP) said: “Fueled by the pharmaceutical industry’s move to make clinical trials more patient-centric and operationally efficient, the demand for patient engagement technologies is growing. This growth is a testament to the industry’s focus on delivering a new breed of solutions with a mission to improve the lives of patients and the clinical research sites supporting them.”
mProve Health is Lee’s fourth mobile technology venture. Co-founded with Denis Curtin, PhD, CSO, a pharmacologist and pharmaceutical industry veteran, the company is challenging the legacy of patient technology used in clinical research studies. By expanding mProve’s foothold in Washington, DC, the leadership team continues to remain actively involved with regulators shaping the future of mHealth policy.
To learn about mProve Health visit www.mprove.com.
About mProve Health
mProve Health is a leading provider of mobile technologies for life science companies, helping them connect better with patients. The company offers industry-grade, regulatory compliant mobile solutions for patient recruitment, patient engagement, and electronic patient reported outcomes (ePRO). mProve’s applications are used by 15,000 clinical research sites in over 60 countries and are translated in over 35 languages to support patients across the globe. The company was founded in 2010 by Jeff Lee, CEO, an entrepreneur and mobile engagement strategist who founded three prior successful ventures and Denis Curtin, PhD, CSO, a pharmacologist and pharmaceutical industry veteran.
mProve Health Contacts
Media: Michelle Valentine, firstname.lastname@example.org
Other Inquiries: Laurie Thackeray, email@example.com
BYOD has been a buzzword in the clinical trial space since mProve Health got started in 2010. We have seen the movement go from risky and heavily-hyped to a conservatively accepted. From our start in ePRO, we’ve been driving the BYOD bandwagon. Now, though, we want to pull over and ask for directions. That stopover is CYOD.
mProve Health recently had the privilege of adding “artistic services” to its accomplishments! We were pleased that Eli Lilly and Company invited us to take part in The Hero’s Journey art project, and we submitted our contribution last week.
Embracing the trend of patient centricity, Lilly launched The Hero’s Journey as a collaborative, installation-style artwork that celebrates the contributions of clinical trial patients. In the literary tradition, the Hero’s Journey is a classic narrative of the protagonist battling various obstacles, always for the greater good. The hero doesn’t always make it, but their work makes life easier for those who come after them.
Trial subjects are asked to donate their time and bodies, sometimes as healthy volunteers and sometimes as a last chance for treatment. As we understand it, the art project is an attempt to bring the patient contribution out of the shadow of leading drug developers and researchers. It reminds us that patient participants in a trial are perhaps the most important contributors to modern pharmacology.
Artist John Magnan was brought on to design the piece for Lilly. Using wood, he created three teardrop structures, which will collectively hold 1,000 brick-sized wooden blocks. Lilly shipped these bricks to all sorts of people involved in clinical research, from their own employees to CROs to vendors like us. (When we were first asked to contribute, we worried that Lilly was using real bricks and felt for the postal worker who had to carry them all around.) We were all encouraged to design the brick in our interpretation of the Hero’s Journey theme, using whatever media we had available.
We see our products as a signposting tool for patients already on a treatment journey. The decisions about how to seek treatment and whether to engage in clinical trials are theirs alone–as they should be. What we always aim to do is to provide additional support so that the patients’ decisions are, perhaps, a little easier to make.
We are also excited that the patient centricity trend is pushing pharma towards giving patients a stronger, louder voice in trial design and in their individual treatment. One of the most wonderful things is seeing how a group of patients, by consenting to become data points in the study results, collect themselves into an impactful whole. One datum by itself is usually insignificant, but data compounded push lifesaving treatments further towards the market.
Our Trial Guide app uses path and guidepost symbolism already, so starting with that imagery was an easy decision for the informal mProve brick committee. It was important to us that each patient be represented, and that not all patients be shown as following the same journey; some are on the road from the beginning, while others wander in a bit later. We chose oil paints to show each patient as a unique data point, flowing down a path toward blue skies until they become indistinguishable parts of a larger whole.
Learn more about The Hero’s Journey here: https://www.lillytrialguide.com/en-US/heros-journey-art. We encourage anyone who has the opportunity to go see it, and to look for the mProve brick!